Abstract:Pancreatic neuroendocrine neoplasms (pNENs) are rare and highly heterogeneous tumors originating from pluripotent stem cells with neuroendocrine differentiation in the pancreas, constituting approximately 3% of all pancreatic tumors.[1] The global incidence of pNENs has been increasing recently, and most cases are sporadic and more common in women.[1,2] pNENs are clinically divided into functioning and non-functioning tumors depending on whether the tumors are accompanied by a clinical syndrome related to specific hormone overproduction. Functioning tumors are usually diagnosed during the early evaluation of hormonal syndromes, whereas most non-functioning pNENs are accidentally found during imaging studies and endoscopies for other complaints, such as the mass effect of local growth or secondary symptoms owing to metastasis.[2,3] The etiology of pNENs is partially known and may be related to genetic mutations, family history of cancer, cigarette smoking, alcohol consumption, and other risk factors.[4,5] Although most pNENs are sporadic and likely carry somatic mutations in death domain-associated protein 6 (DAXX) and ATP-dependent helicase (ATRX),[6] they may develop in patients with hereditary endocrinopathies, including multiple endocrine neoplasia type 1 (MEN1),[7] von Hippel–Lindau (VHL) syndrome,[8] neurofibromatosis type 1 (NF1),[9] and Tuberous Sclerosis Complex (TSC).[10] Evidence for diagnosing, staging, and treating pNENs has emerged over the past few years, particularly in original trials among the Chinese population. Based on this, the Pancreatic Tumor Group of the Oncology Society of the Chinese Medical Association convened a writing committee of multidisciplinary experts to compile Chinese Medical Association Consensus for the Standardized Diagnosis and Management of Pancreatic Neuroendocrine Neoplasms (2022). This consensus will positively influence standardizing pNEN diagnosis and treatment in China, improve patient prognosis, and optimize medical resources. Diagnosis Clinical manifestations Functioning tumors account for approximately 34% of pNENs and include insulinomas, glucagonomas, gastrinomas, vasoactive intestinal peptide tumors (VIPomas), somatostatinomas, and adrenocorticotropic hormone (ACTH)-producing tumors.[3,11] Clinical manifestations of specific syndromes arising primarily from secreted hormones have been presented[11] [Table 1]. Table 1 - Clinical manifestations of functioning pNENs. Tumor type Percentage Primarily secreted hormones Main symptoms Insulinoma 40–60% Insulin Whipple's triad: symptoms and signs of hypoglycemia (tremors, palpitations, hunger, etc.), especially CNS symptoms (cognitive impairment, seizures, coma, etc.); low blood plasma glucose level (<2.8 mmol/L); relief of symptoms when glucose level is increased. Gastrinoma 20–50% Gastrin ZES: refractory peptic ulcer, gastroesophageal reflux symptoms, abdominal pain, diarrhea, etc. Glucagonoma Rare Glucagon Glucagonoma syndrome: NME, diabetes mellitus, venous thrombosis, intermittent diarrhea, weight loss, depression, and other psychiatric symptoms. Somatostatinoma Rare Somatostatin Somatostatinoma or "Inhibitory" syndrome: a triad of mild diabetes mellitus, cholelithiasis, and diarrhea/steatorrhea; other symptoms such as gastric acid deficiency and weight loss. ACTH-producing tumor Rare ACTH Cushing syndrome: obesity, acne, rounded face, hirsutism, hypertension, fatigue, depression, dorsocervical fat pad, impaired glucose tolerance, proximal muscle weakness, menstrual irregularities, infertility, etc. VIPoma Rare VIP Verner–Morrison syndrome (pancreatic cholera syndrome): watery diarrhea, hypokalemia, dehydration, gastric acid deficiency, etc. Carcinoid Rare 5-HT (serotonin), tachykinin Carcinoid syndrome: flushing, diarrhea, bronchospasm, heart valve disease, etc. ACTH: Adrenocorticotropic hormone; NME: Necrolytic migratory erythema; pNENs: Pancreatic neuroendocrine neoplasms; VIPoma: Vasoactive intestinal peptide tumor; ZES: Zollinger–Ellison syndrome; CNS: central nervous system; 5-HT: 5-hydroxyptamine. Non-functioning tumors represent 66% of pNENs. The incidence could be higher than that previously reported owing to the absence of a typical clinical presentation in the early stage.[3,12] The clinical manifestations of non-functioning tumors are non-specific and are primarily related to the local compression effects of primary lesions and metastases, including regional pain, jaundice, abnormal bowel movements, fever, and gastrointestinal (GI) bleeding. Laboratory tests Peripheral blood biomarker test Serum chromogranin A (CgA), the most critical universal biomarker for neuroendocrine tumors (NETs), is used to assist in diagnosis and to assess the response and prognosis.[13,14] The efficacy of CgA in diagnosing and treating pNENs may be influenced by the tumor type, primary site, tumor differentiation, tumor burden, and secretory functionality. Owing to the absence of unified clinical standards for CgA testing in China, more caution is required in applying and interpreting CgA testing.[14] Neuron-specific enolase (NSE) levels are significantly elevated in some patients with high-grade NETs or neuroendocrine carcinomas (NECs). Baseline NSE levels and post-treatment changes are strongly associated with prognosis.[15,16] Similarly, serum procalcitonin levels, mostly elevated in G3 NETs and NECs, can be used for tumor monitoring.[17] Furthermore, other tumor serum biomarkers, including carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 199 and CA125, may be valuable for diagnosing and predicting recurrence, metastasis, and prognosis of pNENs; however, they lack specificity.[18] Laboratory tests for functioning pNENs Specific biochemical indicators and corresponding hormone levels should be monitored closely according to the tumor type, and endocrinologists should be consulted for qualitative, localization, and functional assessments of the tumor. Insulinoma The cut-off value for hypoglycemia was 55 mg/dL, or 3 mmol/L. It is characterized by plasma insulin ≥3.0 μIU/mL (18 pmol/L), plasma C-peptide ≥0.6 ng/mL (0.2 nmol/L), plasma proinsulin ≥5.0 pmol/L (without sulfonylurea), and insulin release index: plasma insulin (μIU/mL)/plasma glucose (mg/dL) >0.4. The 48-h or 72-h fasting test was performed to establish a diagnosis of endogenous hyperinsulinemia in a few patients with asymptomatic hypoglycemia and those with high suspicion of insulinoma without hypoglycemic episodes.[19] Gastrinoma Serum gastrin >1000 ng/L and gastric acid pH <2. Stimulation tests, that is, secretin stimulation, calcium stimulation, and standard meal tests, are performed for patients with serum gastrin levels >200 ng/L and <1000 ng/L. Serum gastrin levels in patients with gastrinomas are characterized by fasting hypergastrinemia[20] (>150 pg/L), a rapid and significant increase in serum gastrin after intravenous secretion, and a significant increase in serum gastrin after calcium injection. (1) The secretin stimulation test is the most valuable for identifying gastrinomas. Pure porcine secretin (2 U/kg) is injected intravenously within 30 min, and the serum specimen is measured using a radioimmunoassay. In patients with gastrinoma, the serum gastrin concentration increases rapidly (within 2–10 min) by at least 200 pg/L after injection and gradually returns to the pre-injection level. (2) Calcium stimulation test: This involves measuring radioimmuno-labeled gastrin in blood samples drawn 30 min before and every 30 min after calcium injection for a total of nine times. Eighty percent of patients with gastrinoma show increased gastrin release after calcium injection, and most of them show a significant increase in gastrin concentration (>400 pg/L). Gastrin concentration usually peaks shortly after injection. (3) Standard meal test: This test involves using one slice of bread, 200 mL of milk, one hard-boiled egg, and 50 g of cheese (containing 20 g fat, 30 g protein, and 25 g carbohydrates). Serum gastrin levels are measured at 15 min and 0 min before and every 15 min until 90 min after ingestion. Ectopic ACTH syndrome (1) Twenty-four-hour urine-free cortisol (UFC): Retaining of 24-h urine for cortisol level testing. A minimum of two tests should be performed. It is significantly elevated in patients with ectopic ACTH syndrome. (2) The circadian rhythm of serum cortisol: Cortisol levels should be measured at 8:00, 16:00, and 0:00. If the serum cortisol is >50 nmol/L (1.8 μg/dL) at 0:00 or >207 nmol/L (7.5 μg/dL) in the awake state, Cushing's syndrome is possibly indicated. (3) The 1 mg-overnight dexamethasone suppression test: The normal cut-off serum cortisol level after dosing is <50 nmol/L (1.8 μg/dL). However, serum cortisol levels cannot be suppressed in patients with ectopic ACTH syndrome. (4) Classical low-dose dexamethasone suppression test: In normal individuals, the 24-h UFC is <27 nmol, and serum cortisol is <50 nmol/L (1.8 μg/dL) on day 2 after oral dexamethasone. However, serum cortisol levels cannot be suppressed in patients with ectopic ACTH syndrome. (5) Plasma ACTH: A plasma ACTH level >500 pg/mL (110 pmol/L) is often indicative of ectopic ACTH syndrome. (6) Classical high-dose dexamethasone suppression test: If 24-h UFC or blood cortisol is suppressed by over 50% of the control value, Cushing's disease is suggested; otherwise, ectopic ACTH syndrome is indicated. (7) Bilateral inferior petrosal sinus sampling (IPSS) + desmopressin (DDAVP) stimulation test: The ACTH ratio of the inferior petrosal sinus to peripheral plasma ≥2 and/or ≥3 after DDAVP stimulation suggests Cushing's disease, otherwise ectopic ACTH syndrome is indicated.[21] VIPoma Normal individual fasting serum VIP ranges from 0 pg/mL to 170 pg/mL, with a mean of 62 ± 22 pg/mL. A fasting serum VIP level >200 ng/L is critical for diagnosing VIPoma. Serum VIP levels are significantly elevated in patients with VIPoma, with a mean value of 956 ± 285 pg/mL. Percutaneous transhepatic portal vein catheterization (PT-PC), which involves placing the catheter into the splenic vein and portal vein trunk to measure VIP concentrations, facilitates qualitative assessment and localization evaluation. Somatostatin and its derivative octreotide are effective experimental treatments. Other rare functioning tumors The corresponding hormones should be examined according to the clinical symptoms of the patient. Imaging studies Ultrasound, contrast-enhanced ultrasonography (EUS), ultrasound endoscopy, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)-CT, PET-MRI, and somatostatin receptor imaging (SRI) are common imaging modalities used for pNENs.[22,23] SRI is a specific imaging technique used for pNENs. The degree of focal tumor uptake is proportional to the number of somatostatin receptors (SSTRs) expressed on the surface of NEN cells. Owing to the many surface SSTRs in G1 and G2 NETs, the diagnostic accuracy and specificity of SRI reaches 85% for primary and metastatic lesions. Therefore, SRI has great advantages in qualitative diagnosis, primary foci localization, clinical staging, pathological grading, treatment selection, efficacy follow-up, and prognostic assessment of G1 and G2 NETs. However, for G3 NETs and NECs, the diagnostic sensitivity of SRI decreases, having 40–60% accuracy owing to the reduction in their cell surface SSTRs. Differential diagnosis The imaging presentation of pNENs should be differentiated from that of solid pseudopapillary tumors (SPT) of the pancreas, pancreatic cystadenomas, intraductal papillary mucinous neoplasms (IPMN), and pancreatic cancer [Table 2]. The clinical manifestations of functioning and non-functioning tumors should be distinguished from similar presentations caused by other diseases. Table 2 - Imaging diagnosis and differential diagnosis of pNENs. Disease Origin Growth pattern Calcification Growth rate Enhancement appearance Other characteristics pNEN Pancreatic parenchyma Swelling Yes Slow, faster in case of malignant transformation Rich blood supply SPT of the pancreas Pancreatic parenchyma Swelling Yes Slow Solid component enhanced Mostly among young adult women Pancreatic cystadenoma Pancreatic parenchyma Swelling Yes Slow, faster in case of malignant transformation Lack of blood supply Serous cystadenoma has a very low rate of malignancy, while mucinous cystadenoma can have malignant transformation IPMN Pancreatic duct Swelling Yes Slow, faster in case of malignant transformation Solid component enhanced Branched type IPMN has a low malignant rate, while main pancreatic duct type IPMN has a high malignant rate Pancreatic cancer Pancreatic duct Swelling + Infiltration None Fast Most lack of blood supply Mostly among middle-aged and elderly IPMN: Intraductal papillary mucinous neoplasms; pNENs: Pancreatic neuroendocrine neoplasms; SPT: Solid pseudopapillary tumor. Pathology Definition of pathology The 2019 World Health Organization (WHO) classification of digestive system tumors [Supplementary File 1, https://links.lww.com/CM9/B718] classifies pNENs into well-differentiated NETs, poorly differentiated NECs, and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs). pNETs are well-differentiated tumors with neuroendocrine features and express neuroendocrine markers, as determined using immunohistochemistry (IHC). According to the mitotic count and Ki-67 proliferation index, pNETs can be classified into G1 (low grade), G2 (intermediate grade), and G3 (high grade).[24,25] The prognosis of G3 pNETs is worse than that of G1 or G2 pNETs but better than that of pNECs.[26,27] Differences in the genomic landscape between pNETs and pNECs support that they belong to different tumor entities. On gross appearance, pNENs are grayish-white, grayish-red, and round masses, mostly solitary or multinodular. The tumors have a soft texture, and bleeding can be observed. pNENs have a characteristic "organoid" arrangement of uniformly round or small polygonal tumor cells with nesting, striated, ribbon-like, or glandular duct-like patterns. The tumor cells exhibit coarsely stippled or finely granular nuclei with visible nucleoli in some cells. pNENs are positive for CgA, synaptophysin (Syn), and CD56 in IHC. The presence of hormones (including insulin, gastrin, VIP, and somatostatin) may be observed using IHC staining. However, the diagnosis of functioning tumors should be based on specific clinical presentations and not positive hormone IHC staining, as non-functioning tumors also secrete hormones. Histological classification and grading The 2019 WHO Classification of Digestive System Tumors (5th edition)[24] is recommended for the classifying and grading pNENs [Supplementary File 1, https://links.lww.com/CM9/B718]. Tumor grading involves incorporating the mitotic count and Ki-67 proliferation index according to the WHO criteria. If both are used and these are discordant, the higher grade should be used for the classification. The Ki-67 proliferation index is determined by counting tumor cells in areas with the highest labeling (i.e., "hotspots). "Eyeball estimates" is not recommended, and at least 500 cells should be counted[25] [Supplementary File 2, https://links.lww.com/CM9/B718]. Pathologic reporting Standardized pathology reports of pNETs and pNECs should include the surgical approach, histological diagnosis, tumor size and amount, tumor site, margin status, adjacent tissues and organs, presence of lymph node metastases, presence of vascular or perineural invasion, and tumor-node-metastasis (TNM) stage. Furthermore, the pathologist should assess the tumor grade and report tumor differentiation, mitotic count, and Ki-67 index. Further assessments can be included if IHC or molecular assays are performed. Whether the tumor is functioning is a clinical and not histological diagnosis, usually not included in the pathology report [Table 3]. Table 3 - Standardized pathology report of pNENs. Specimen type: surgical resection or biopsy Location (anatomy site of specimen) Tumor size (including at least the largest diameter) and amount* Depth and extent of tumor invasion* Vascular and perineural invasion* Mitotic count and Ki-67 index Neuroendocrine markers: CgA and Syn, CD56 Margin status Lymph node metastases Other related changes Diagnosis (according to the 2019 WHO criteria) Original site + NET (G1/G2/G3)/NEC + secondary diagnosis (if required) *Not necessary for biopsy specimens. CgA: Chromogranin A; NET: Neuroendocrine tumor; NEC: Neuroendocrine carcinoma; pNENs: Pancreatic neuroendocrine neoplasms. Staging For pNETs staging, the 2017 American Joint Committee on Cancer (AJCC) Staging Manual (8th edition) is recommended [Supplementary Files 3 and 4, https://links.lww.com/CM9/B718]. The corresponding criteria for pancreatic cancer are recommended for pNEC staging.[28] Treatment Treatment principles pNENs are highly heterogeneous tumors and managing them is challenging. A comprehensive evaluation of the functional status, tumor site, differentiation, Ki-67 index, SSTR expression, tumor burden, and disease progression status should be performed first to maximize patient benefits. Surgery-based treatment is suggested to achieve a radical cure, control tumor growth, manage hormone secretion-related symptoms, and improve survival.[29] Surgical treatment Principles of surgical treatment Surgery is the primary treatment and only possible cure for pNENs.[29] The aim of surgery is to achieve R0 resection. Therefore, we should consider the tumor biology, anatomical features, major organ function, general condition of the patient, and the risks and benefits of surgery when formulating the surgical strategy.[29,30] Aggressive surgery is recommended for patients with functioning pNETs, particularly those with uncontrolled symptoms. For low- or intermediate-grade non-functioning pNETs, watchful surveillance is acceptable if the tumor is small (usually <2 cm)[31]; otherwise, surgical resection is recommended. In patients with pNECs, surgical procedures should be performed following those performed for pancreatic cancer. Preoperative evaluation Preoperative evaluation of pNENs should include the following: (1) General condition of the patient: Including age, major organ function, performance status, and comorbidities. For patients with carcinoid syndrome, echocardiography should be performed to evaluate the cardiac and valve functions. (2) Tumor functionality: Specific biochemical indicators and corresponding hormones, such as insulin, gastrin, VIP, plasma ACTH, 24-h UFC, and plasma cortisol, should be tested. Endocrinologists can be consulted for tumor localization and qualitative and functional assessments preoperatively. (3) Tumor biology: Different imaging techniques such as CT, MRI, EUS, 68Ga-DOTA-PET/CT, and 18F-FDG/PET-CT are recommended for tumor staging, and image-guided fine-needle aspiration biopsy (FNA) can be performed for pathological grading of primary and/or metastatic foci.[25,32] (4) Resectability: The resectability of pNENs can be evaluated using contrast-enhanced CT or MRI. (a) Resectable pNENs: The invasion of major arteries (superior mesenteric artery [SMA], celiac axis [CA], and common hepatic artery [CHA]) and veins (superior mesenteric vein [SMV] and portal vein [PV]) should be absent. If the SMV or PV is involved, the abutment should be ≤180° without vein contour irregularity; for less malignant functioning pNENs treatable through resection or enucleation, the relationship between the tumor and the main pancreatic duct should be evaluated. (b) Borderline resectable pNENs: The tumor may invade the CA (for pancreatic body/tail tumors), CHA, or SMA with an abutment ≤180°, or the abutment >180° (usually CHA and CA) whereas combined arterial resection and reconstruction is feasible; the tumor may invade the SMV/PV with the abutment >180° or cause vein contour irregularity/segmental thrombosis, while combined arterial resection and reconstruction is feasible. (c) Unresectable pNENs: The tumor may encase the CA, SMA, or CHA >180° or invade the aorta abdominalis where combined vascular resection is unfulfilled, or vascular resection and reconstruction are not achievable owing to embolization of the SMV and PV. (d) Evaluation of metastases: Regional lymph nodes and distant metastases (e.g., the liver) should be evaluated, as should the site, amount, and resectability of metastatic foci. (5) Serum biomarkers: Baseline levels of CgA, NSE, alpha-fetoprotein (AFP), CEA CA 199, CA125, and other serum biomarkers should be evaluated to facilitate postoperative follow-up and monitoring. (6) Evaluation of hereditary pNENs: MEN1, VHL, NF1, and TSC1/2 are primarily included. Preoperative preparation for functioning pNENs: The symptoms and syndromes caused by excessive hormone secretion should be managed actively to ensure perioperative patient safety. For patients with insulinomas, close monitoring of blood glucose levels is required. Glucose supplementation can be used to improve hypoglycemic symptoms, and diazoxide can be used to suppress insulin secretion. Proton pump inhibitors (PPIs) or somatostatin analogs (SSAs) are suggested for gastrinomas to control diarrhea, peptic ulcers, and other relevant symptoms. For VIPomas, SSAs have been suggested to control diarrhea and correct electrolyte and fluid balance disorders. For glucagonomas, low-molecular-weight heparin (LMWH) can be used to prevent thrombosis, and SSAs can be used to manage necrolytic migratory erythema. Preoperative SSAs should be used to prevent carcinoid crises for patients with carcinoid syndrome. Resectable locoregional pNENs Surgery should be performed in patients with resectable locoregional pNENs to improve their prognosis. The surgical strategy primarily depends on the anatomical location of the gland, size, multifocality, extent (localized or metastatic), tumor grade, and the involvement of adjacent organs. Functioning pNENs: Patients with locoregional sporadic functioning pNENs should undergo more active surgical resection to relieve hormone-related symptoms, reduce medication dosage, and improve overall survival. (1) Insulinomas have a low malignant potential and favorable tumor biology; therefore, function-preserving pancreatectomy is preferred. Enucleation should be considered for peripheral insulinomas located superficially; however, if they are deeply located with pancreatic duct involvement, pancreatoduodenectomy is feasible for tumors of the pancreatic head, whereas distal pancreatectomy or partial pancreatectomy is feasible for tumors of the body and tail. Lymph node dissection is not routinely required. (2) Other functioning pNENs often have a higher malignant potential, such as gastrinomas, glucagonomas, and VIPomas; therefore, regular excision and regional lymph node dissection are recommended, which is consistent with the surgical principles of non-functioning pNENs. Local resection and lymph node dissection can be considered for tumors <2 cm. (3) Surgical resection is recommended for MEN1-associated functioning pNENs except for unresectable diffuse metastatic diseases. Multidisciplinary evaluation of the functionality of the extrapancreatic glands and corresponding treatments are recommended preoperatively. Gastrinoma is the most common MEN1-associated functioning pNEN; however, no consensus has been reached on the indications and timing of surgery. Most patients are well-managed with long-term survival using PPIs alone. Surgical resection is recommended for tumors measuring 2–3 cm owing to the significantly increased risk of liver metastasis. Similarly, surgical resection is recommended for MEN1-associated insulinoma and glucagonoma. Non-functioning pNENs: Patients with locoregional non-functioning pNENs should consider undergoing surgical resection if no other comorbid life-threatening conditions or high surgical risk is present. (1) For non-functioning G1/G2 pNETs <1–2 cm, in the absence of invasive family history, imaging, or biopsy-confirmed metastasis, comprehensively evaluating the surgical risk, tumor location, and other comorbidities is recommended, and watchful surveillance is acceptable. For G2 pNETs, surgical treatment should be more active. For patients with significant progression (usually defined as a volume increase >20%) during follow-up, evidence of regional lymph node metastasis or local invasion, pancreatic duct dilatation, or obstructive jaundice, prompt surgery should be performed. (2) Non-functioning pNETs >2 cm should be considered for surgery, and regular pancreatectomy (combined resection of adjacent organs) with routine regional lymph node dissection is recommended. (3) The surgical approach depends on the general condition of the patient, the site, and number of tumors. (a) Local resection and minimally invasive surgery are recommended for relatively small non-functioning G1/G2 pNETs. For non-functioning pNETs measuring 1–2 cm, lymph node dissection should be considered during surgical resection despite the relatively low risk of lymph node metastasis. Furthermore, for tumors located in the pancreas head and hook, adjacent to the main pancreatic duct, or multifocal tumors in the pancreas, the surgical approach should be decided based on a case-specific assessment, and regular pancreatectomy is usually recommended. (b) Standard radical resection should be performed for non-functioning pNETs >2 cm. Pancreatoduodenectomy with lymph node dissection can be considered for pancreatic head tumors, whereas distal pancreatectomy combined with splenectomy and lymph node dissection is feasible for pancreatic body and tail tumors. (c) Surgical treatment for patients with MEN1-associated non-functioning pNETs is similar to that for those with sporadic tumors, while a notable exception is multifocal pNETs in patients with MEN1. The value of surgery remains controversial in this population; therefore, aggressive surgical strategies are not recommended. Minimally invasive surgery for pNENs: Laparoscopic or robot-assisted surgery has reduced intraoperative bleeding, a lower incidence of critical postoperative complications, and a shorter hospital stay, with comparable long-term outcomes to open surgery.[33] Thus, it can be applied if technically feasible in individual medical centers. Borderline resectable and locally advanced pNENs Locally advanced pNENs are defined as: (1) Tumors of the pancreatic head encase SMA/CA >180°, tumors of the pancreatic body/tail encase SMA/CA >180° or the tumor invades the CA and aorta abdominalis. (2) Tumor results in the SMV and PV embolization, and vascular resection and reconstruction are impossible. Aggressive surgical treatment is recommended in patients with borderline resectable or locally advanced pNETs. For pNENs invading the surrounding large vessels (e.g., the PV, SMV, SMA, CA, and CHA), combined vascular resection can be the preferred treatment modality while ensuring a radical cure. (1) Surgery is recommended for patients with locally advanced functioning pNENs regardless of the tumor size. Even if R0 resection cannot be achieved, cytoreductive surgery is usually recommended to alleviate hormone-related symptoms and reduce the dosage of related medications. (2) For G1/G2 non-functioning pNETs in the locally advanced stage, combined resection of the primary site and involved organs or tissues and vascular reconstruction can be considered. (3) For locally advanced non-functioning pNENs, despite the controversy in surgical value for patients less likely to achieve R0/R1 resection, effective cytoreductive surgery (usually defined as >90% tumor resection) can relieve patient symptoms and may improve long-term prognosis. (4) Upfront surgery is not recommended for patients with locally advanced G3 pNETs and pNECs, whereas neoadjuvant therapy may be considered because it might increase the R0 resection rate and improve patient prognosis. Palliative surgery should only be performed in patients with tumor-related complications (e.g., GI bleeding, obstruction, or perforation) in whom conservative treatments have failed. Metastatic pNENs Surgical treatment for metastatic pNENs should be comprehensively evaluated based on the age and general condition of the patient, functionality and tumor grade, and the amount and distribution of metastases.[29,30] Although the surgical value for patients less likely to achieve radical resection remains controversial, adequate cytoreductive surgery for >90% of the tumor burden, including primary and metastatic diseases, may provide symptomatic relief and improve long-term prognosis. Even primary tumor resection alone can prolong the survival of patients with metastatic pNENs. Metastatic functioning pNENs: For patients with metastatic-functioning pNENs, cytoreductive surgery is recommended to alleviate hormone-related symptoms, reduce the dose of medication, control tumor growth, and prolong survival.[34] Preoperative treatments, including systemic and liver-directed locoregional (e.g., transarterial chemoembolization [TACE] and radiofrequency ablation [RFA]) therapies, are recommended. G1/G2 non-functioning pNETs with liver metastases: Surgery should be planned according to the type of liver metastasis, and R0/R1 resection should be pursued.[11] (1) For patients with resectable primary tumors and type I liver metastases, all primary and metastatic lesions should be significantly resected in patients with resectable primary tumors and type I liver metastases.[35,36] Upfront treatments for liver metastases are recommended in patients who may require pancreaticoduodenectomy.[36,37] (2) For patients with type II liver metastases, simultaneous or staged resection is suggested if >70% (preferably >90

Role of serum CgA determination for neuroendocrine neoplasma

Application of Serum Chromogranin A in Clinical Diagnosis and Efficacy Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasm

Chromogranin A As a Marker for Diagnosis, Treatment, and Survival in Patients with Gastroenteropancreatic Neuroendocrine Neoplasm.

Use of Chromogranin A for Monitoring Patients with Pancreatic Neuroendocrine Neoplasms

Circulating Chromogranin A As A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.

Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.

Combined test of serum CgA and NSE improved the power of prognosis prediciton of NF-pNETs.

[Therapeutic Efficacy Analysis of Endoscopic Combined with Serological Diagnosis Strategy and Endoscopic in G1 and G2 Gastric Neuroendocrine Neoplasms].

The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.

Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms

Performance of double-antibody sandwich ELISA for chromogranin A determination

Significance of Chromogranin A in Diagnosis and Prognosis of Neuroendocrine Tumors

A Comparative Analysis of Chromogranin A and Inflammatory Cytokines in Patients with Neuroendocrine Tumors

The Role of Elevated Serum Procalcitonin in Neuroendocrine Neoplasms of Digestive System

Relationship between the level of serum chromogranin A and liver metastases of non-functional pancreatic neuroendocrine tumors

Diagnostic Value Of Circulating Chromogranin A For Neuroendocrine Tumors: A Systematic Review And Meta-Analysis

Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas

Circulating Chromogranin A as Surveillance Biomarker in Patients with Carcinoids – The CASPAR Study

Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages

Chinese Medical Association Consensus for Standardized Diagnosis and Treatment of Pancreatic Neuroendocrine Neoplasms

[Prognostic Value of Carcinoembryonic Antigen, Alpha Fetoprotein, Carbohydrate Antigen 125 and Carbohydrate Antigen 19-9 in Gastroenteropancreatic Neuroendocrine Neoplasms].